Nuvectis Pharma Net Income Over Time
| NVCT Stock | USD 8.76 0.04 0.45% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Nuvectis Pharma Performance and Nuvectis Pharma Correlation. Is there potential for Biotechnology market expansion? Will Nuvectis introduce new products? Factors like these will boost the valuation of Nuvectis Pharma. Anticipated expansion of Nuvectis directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Nuvectis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Understanding Nuvectis Pharma requires distinguishing between market price and book value, where the latter reflects Nuvectis's accounting equity. The concept of intrinsic value - what Nuvectis Pharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Nuvectis Pharma's price substantially above or below its fundamental value.
It's important to distinguish between Nuvectis Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Nuvectis Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Nuvectis Pharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Nuvectis Pharma and related stocks such as Innate Pharma, Compugen, and Milestone Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IPHA | (6.1 M) | (7 M) | (3.2 M) | (2.9 M) | (19.6 M) | (6.7 M) | 12.6 M | (48.4 M) | 3 M | (20.8 M) | (64 M) | (52.8 M) | (58.1 M) | (7.6 M) | (49.5 M) | (44.5 M) | (42.3 M) |
| CGEN | (8.1 M) | (12 M) | (13.6 M) | (14.1 M) | (11.1 M) | (20.2 M) | (31.5 M) | (37.1 M) | (22.6 M) | (27.3 M) | (27.3 M) | (32.9 M) | (33.7 M) | (18.8 M) | (14.2 M) | (12.8 M) | (13.4 M) |
| MIST | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (23.2 M) | (55.2 M) | (50 M) | (42.9 M) | (57.1 M) | (59.7 M) | (41.5 M) | (37.4 M) | (39.2 M) |
| RANI | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (16.7 M) | (8.3 M) | (30.6 M) | (34 M) | (30 M) | (27 M) | (28.4 M) |
| CRDF | (5.4 M) | (2.2 M) | (11.6 M) | (11.8 M) | (14.3 M) | (27.5 M) | (39.2 M) | (24.9 M) | (16.5 M) | (16.4 M) | (19.3 M) | (28.3 M) | (38.7 M) | (41.4 M) | (45.4 M) | (40.9 M) | (38.8 M) |
| ARMP | (5.1 M) | (3.8 M) | (1.1 M) | (64.6 M) | 23.1 M | (516 K) | (18.8 M) | (12.8 M) | (12.1 M) | (19.5 M) | (22.2 M) | (23.2 M) | (36.9 M) | (69 M) | (18.9 M) | (17 M) | (17.9 M) |
| MOLN | 7.1 M | 7.1 M | 7.1 M | 7.1 M | (2.3 M) | (148.8 K) | (18.6 M) | (25.4 M) | (37 M) | (36.3 M) | (62.8 M) | (63.8 M) | 117.9 M | (62 M) | (54 M) | (48.6 M) | (46.2 M) |
| SAVA | (4.5 M) | (2.6 M) | (3.4 M) | 31.5 M | (12.4 M) | (14.1 M) | (14.8 M) | (11.9 M) | (6.6 M) | (4.2 M) | (6.3 M) | (31.8 M) | (72.5 M) | (97.2 M) | (24.3 M) | (21.9 M) | (23 M) |
Nuvectis Pharma and related stocks such as Innate Pharma, Compugen, and Milestone Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Nuvectis Pharma financial statement analysis. It represents the amount of money remaining after all of Nuvectis Pharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Nuvectis Pharma | NVCT |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1 Bridge Plaza, |
| Exchange | NASDAQ Exchange |
USD 8.76
Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.